Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may prevent dangerous blood pressure spikes in thyroid surgery

NCT ID NCT07434206

Disease control Sponsor: South Egypt Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dexmedetomidine, a sedative, can safely control blood pressure and heart rate during surgery to remove active thyroid tumors. Eighty adults aged 20 to 65 are randomly assigned to receive either dexmedetomidine or the standard drug labetalol. The goal is to see if dexmedetomidine provides smoother blood pressure control without causing dangerous drops afterward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexmedetomidine (Precedex)
What this could lead to
If it works, this could offer a safer way to manage blood pressure spikes during thyroid tumor surgery, reducing complications.
What could go wrong
This is a mid-stage trial with only 80 participants, so results may not apply to everyone. The drug may not outperform standard treatments and could cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients subjected to thyroid resection surgeries for active thyroid tumors. * The enrolled age will be from 20 years to 65 years * ASA, I-III and NYHA, I-II. Exclusion Criteria: * ASA physical status \>III and NYHA \>II, * body mass index \>40 kg/m2, * pregnant women, * preoperative opioid consumption, * Allergy to dexmedetomidine * Contraindications as hypotension or cardiovascular compromise * Unwilling to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid neoplasms

Contacts and locations

Locations

  • south Egypt cancer institute

    Asyut, 171516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.